Addiction is a complex, relapsing, chronic disease, which can carry serious health and social consequences. The Mundipharma network of independent associated companies has been working in addiction medicine since 1999, with a particular emphasis on heroin dependency. We understand well the impact this condition has on patients, their families and wider society. We have also amassed decades of first-hand experience in the science of opioid-based medication, which gives us an excellent base from which to deliver high-quality medicines in this area.
Our efforts in addiction medicine have already resulted in making an opioid agonist treatment available. Our ambition is to provide a broader range of therapeutic options, giving patients the best possible chance to overcome their personal challenges in heroin dependence.
At the same time, we will continue to work with payers, policy experts and patients to drive improvements across the addiction therapy ecosystem in Europe. We will also promote further education of healthcare professionals who are working to support people living with opioid dependency.
Please note that the medicines mentioned may not be available in all countries. Additionally, currently approved indications and presentations may differ between countries. Please always ask a healthcare professional for advice regarding medicines and refer to individual countries for full product indication and local prescribing information.
Substitol ® / Sevre-Long® (morphine sulfate) is a slow release oral morphine capsule for oral substitution therapy (maintenance therapy) in patients with opioid/heroin dependence.
L-Polamidon® (levomethadone) is a levomethadone solution for oral substitution therapy (maintenance therapy) in patients with opioid/heroin dependence.
Nyxoid® (intranasal naloxone spray) is a single use intranasal naloxone spray for use in the emergency reversal of opioid overdose.
Press return to search